You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Compugen's shares were up more than 1,000 percent for the year, leading a group of eight firms whose stocks returned a greater than 100 percent gain.
The firm came under threat of delisting after filing for Chapter 11 bankruptcy protection.
Compugen climbed following two announcements during the month, while Helicos slumped after a placement of its shares with investors.
The upgrade comes a few weeks after Beckman Coulter issued preliminary 2010 EPS guidance.
Compugen's shares jumped 35 percent in early trade after it announced the discovery of a cancer drug target.
Decode's shares sank to a few pennies after the firm filed for bankruptcy protection. Meanwhile, Sequenom rose as it attempts rebound from a major setback in its Down syndrome test development program.
October was a tough month for tech stocks, and biotech stocks in particular. The GWDN Index fell 5 percent, with Affymetrix and Helicos recording the biggest declines for the month.
The money will be used to meet working capital needs and for general corporate purposes.
NPR reports that researchers have developed chimeric embryos as part of work toward growing human organs in animals for organ transplants.
According to the Washington Post, the Biden Administration is set to make changes to federal restrictions on fetal tissue research.
In Science this week: approach to isolated trace DNA from archaic humans from sediments, and more.
Texas Monthly looks into the DNA Zoo being collected by Baylor College of Medicine researchers.